IndraLab
Statements
reach
"Mysm1-deficiency is known to result in p53 activation in hematopoietic cells [XREF_BIBR, XREF_BIBR, XREF_BIBR], indicating that MYSM1 normally represses p53 activation, and suggesting it as a possible target for therapeutic p53 activation in hematological malignancies that retain wild type p53 function."
eidos
"Mysm1-deficiency is known to result in p53-activation in hematopoietic cells [ 19,44,45 ] , indicating that MYSM1 normally represses p53 activation , and suggesting it as a possible target for therapeutic p53-activation in hematological malignancies that retain wild type p53 function ."